Home » Stocks » HRMY

Harmony Biosciences Holdings, Inc. (HRMY)

Stock Price: $38.82 USD 0.21 (0.54%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 2.21B
Revenue (ttm) 109.45M
Net Income (ttm) -73.18M
Shares Out 30.21M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $38.82
Previous Close $38.61
Change ($) 0.21
Change (%) 0.54%
Day's Open 38.27
Day's Range 38.11 - 39.08
Day's Volume 91,571
52-Week Range 30.96 - 51.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 4 weeks ago

PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 17, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...

PRNewsWire - 1 month ago

PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...

GlobeNewsWire - 2 months ago

WAKIX ® (pitolisant) Total Revenue of $45.6 Million for Third Quarter of 2020

PRNewsWire - 2 months ago

PLYMOUTH MEETING, Pa. and CHICAGO, Nov. 11, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...

PRNewsWire - 2 months ago

PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 28, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...

PRNewsWire - 3 months ago

PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...

PRNewsWire - 4 months ago

PLYMOUTH MEETING, Pa. and CHICAGO, Aug.

PRNewsWire - 4 months ago

PLYMOUTH MEETING, Pa. and CHICAGO, Aug.

Seeking Alpha - 4 months ago

U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week

Other stocks mentioned: FIIIU, KYMR, NNOX
PRNewsWire - 4 months ago

Harmony shares began trading on the Nasdaq Global Market under the ticker symbol "HRMY" on August 19, 2020.

Seeking Alpha - 4 months ago

Harmony Biosciences: Interesting Pharmaceutical Public Offering

PRNewsWire - 4 months ago

PLYMOUTH MEETING, Pa. and CHICAGO, Aug. 18, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies f...

About HRMY

Harmony Biosciences Holdings, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Industry
Biotechnology
IPO Date
Aug 19, 2020
CEO
John Charles Jacobs M.B.A.
Employees
150
Stock Exchange
NASDAQ
Ticker Symbol
HRMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 33.95% from the latest price.

Price Target
$52.00
(33.95% upside)
Analyst Consensus: Buy